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Non-Homogenous Poisson Process (NHPP), also known as the Power Law process (PLP) or the Weibull 
Process, is used to evaluate the effectiveness of a given treatment for Stage I & II ductal breast cancer 
patients. The behavior of the shape parameter of the intensity function is examined to evaluate the 
response of a given treatment with respect to its effectiveness for a cancer subject. 
 
Key words: Statistical modeling, power law process, Weibull process, non-homogenous Poisson process, 
intensity function, cancer analysis. 
 
 
Introduction 
Breast cancer (malignant breast neoplasm) is 
cancer originating from breast tissue, most 
commonly from the inner lining of milk ducts or 
the lobules that supply the ducts with milk 
(Sariego, 2010). This study uses the Non-
Homogenous Poisson Process (NHPP), also 
known as the Power Law Process (PLP) or the 
Weibull Process, to evaluate the effectiveness of 
a given treatment for Stage I & II ductal breast 
cancer patients. The behavior of the shape 
parameter of the intensity function is examined 
to evaluate the response of a given treatment 
with respect to its effectiveness for the cancer 
subject. Data from the Surveillance 
Epidemiology and End Results (SEER) Program 
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is used to test the proposed model. This data is 
collected by the U.S. National Institutes of 
Health (NIH) (2010) and includes information 
on incidence, survival and prevalence from 
specific geographic areas representing 26% of 
the U.S. population; the NIH also compiles 
reports on several types of cancer and includes 
mortality rates in the SEER database. 
 
Historical Review 
Many authors have contributed to the 
literature on point processes. Billingsley (1961) 
proposed a statistical inference method for 
Markov processes. Duane (1964) suggested a 
learning curve approach to reliability 
monitoring. Cox and Lewis (1966) studied 
statistical inference problems in point processes 
and their applications. Cox and Isham (1980) 
discussed random collection of point processes, 
and Basawa and Parkasa Rao (1980) studied 
different stochastic processes with the 
applications. Dharmadhikari, et al. (1989) 
estimated the scale parameter of a power law 
process using power law counts. Bain and 
Enelhardt (1991) presented a statistical analysis 
of reliability and compared several life testing 
models. Kingman (1993) discussed methods of 
Poisson Sampling. Tsokos (1997) presented the 
parameter estimation of Power Law Process. 
Rigdon and Basu (2000) proposed several 
statistical methods for the reliability of 
repairable systems using a power law process. 
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Methodology 
The schematic diagram presented in Figure 1 
provides a picture of the database used in this 
study. A randomized data set was generated to 
reduce random errors by performing simple 
random sampling procedures. From a total 
578,134 cancer patients in the SEER database, 
500,000 breast cancer patients’ information was 
randomly selected. Out of these 500,000 breast 
cancer patients, 496,783 are female and 3,217 
are male. The female patients are categorized 
into three different racial groups: Caucasian, 
African-American and Asian (which includes 
others). Within these groups, there are 426,302 
Caucasian, 39,681 African-American, 29,015 
Asian and 1,785 unspecified patients. Within 
each patient group there are four types of breast 
cancer: ductal, medullary, lobular and other 
(unspecified). For each type of breast cancer, 
patients are further divided according to the 
American Joint Committee on Cancer (AJCC) 
Cancer Staging, such as, stage I, II, III, IV and 
others. Breast cancer, particularly the ductal 
form, is a common occurrence among Caucasian 
females; thus, this study focuses on ductal breast 
cancer among Caucasian females. 
 
Caucasian Ductal Cancer Patients in Stage I 
WD stage I stands for Caucasian ductal 
cancer patients in AJCC stage I. Similarly, WD 
stage II, III and IV stand for Caucasian ductal 
cancer patients in AJCC stages II, III and IV. 
WD patients in stage I were divided into two 
groups: (1) patients who are still living, and (2) 
patients who are deceased (see Figure 2). 
Deceased patients were grouped into (1) patients 
who are deceased due to breast cancer and, (2) 
patients who are deceased due to other reasons. 
For those patients who are deceased due to 
breast cancer, different treatment information is 
available. A NHPP was constructed with respect 
to WD stage I patients in order to compare the 
effects of the four different treatments.  
 
Caucasian Ductal Cancer Patients in Stage II 
Caucasian ductal patients in stage II 
were divided into two groups, patients who are 
still living and patients who are deceased (see 
Figure 3).   Deceased   patients   were   further  
divided into groups of patients who (1) are 
deceased due to breast cancer, and (2) patients 
who are deceased due to other reasons. For those 
patients who are deceased due to breast cancer, 
different treatment information is available. A 
NHPP was constructed with respect to WD stage 
II patients in order to compare the effects of the 
four different treatments. 
The most common stages to classify 
breast cancer patients are stages I and II. Thus, 
these are the stages considered herein using the 
NHPP to determine the effectiveness of the four 
different treatments (see Figures 2 and 3). 
 
Non-Homogeneous Poisson Process Analysis 
According to Tsokos (1997), the non-
homogeneous Poisson process (NHPP) is also 
known as the Power Law Process (PLP) or the 
Weibull process (WP), in addition, the NHPP is 
also considered a counting process. Let 
}0),({ ≥ttN  be a counting process with the 
following three properties: 
 
1. 0)( ≥tN . 
 
2. ( )N t  is an integer. 
 
3. If ,s t≤  then )()( tNsN ≤ .  
 
If ts  , then )()( sNtN −  is the 
number of events occurring during the interval 
],( ts . 
A Poisson process is a stochastic 
process in which events occur continuously and 
independently of one another. The Poisson 
process is a collection {N(t): t ≥ 0} of random 
variables, where N(t) is the number of events 
that have occurred up to time t (starting from 
time 0). The number of events between times a 
and b is given as N(b) − N(a) and has a Poisson 
distribution. Each realization of the process 
{N(t)} is a non-negative integer-valued step 
function that is non-decreasing.  
For NHPP, the rate parameter may 
change over time. In this case, the generalized  
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rate function is given as λ(t), thus, the expected 
number of events between time a and time b is: 
 
= baba dtt .)(, λλ                      (1) 
 
Therefore, the number of arrivals in the time 
interval (a, b], given as N(b) − N(a), follows a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Poisson distribution with associated parameter λ, 
a, b as: 
 
a ,b k
a,be ( )P[(N(b)) N(a)) k] , k 0,1,...
k!
−λ λ
− = = =
(2) 
 
A homogeneous Poisson process may be viewed 
as a special case when λ(t) = λ, a constant rate.  
Figure 1: Breast Cancer Data Tree Diagram 
(WD stage I stands for White Ductal cancer patients in AJCC Stage I) 
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Figure 2: Breast Cancer Data Diagram White Ductal Stage I Patients 
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Figure 3: Breast Cancer Data Diagram White Ductal Stage II Patients 
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The mean value function )(tλ  of the process is: 
 
t
0
1
t
0
(t) E(N(t))
v(s)ds
s ds
t .
β−
β
λ =
=
β   
=    α α   
 
=  α 

             (4) 
 
It is known that, if the parameter beta is greater 
than one in survival analysis, then the failure 
time increases; this indicates a decrease in 
survival rate. If beta is less than one in the 
survival analysis, then the failure time decreases, 
meaning the survival rate increases. If beta 
equals one then the failure time is constant and 
the NHPP will become a homogenous Poisson 
process (HPP) (Rigdon & Basu, 2010). 
The NHPP has the intensity function  
 
1t(t) ,  for 0, 0, t 0.
β−β   
ν = α β   α α        
(3) 
 
The unbiased estimator of beta is (Bain 
& Enelhardt, 1991):  
 
U MLE
n
n
i 1 i
n 1ˆ
n
n 1 .
tlog
t
=
− − γβ = ×β
− − γ
=    
                (5) 
 
where γ  is an indicator function. If 1=γ  the 
system will be failure time truncated, meaning 
the system is restricted by a number of tails and 
testing will stop when that number of tails is 
reached. If 0=γ  then the system will be time 
truncated, which means the system is restricted 
by a final failure time and will stop when that 
time is reached.  
The other parameter alpha can be 
calculated by equation 6, below.  
 
β
α
ˆ
1ˆ
n
tn
=
                            (6) 
 
This study belongs to the first case; that is, the 
time of cases has been fixed. Patients were 
divided into four groups according to their 
cancer stage and, within each stage, it is known 
what kind of treatment the patient received, 
including if the patient did not receive any 
radiation treatment at all. Therefore, within each 
stage patients are divided into four groups with 
respect to treatment they received, namely, 
without treatment, treatment 1, 2 or 3. Treatment 
1 refers to beam radiation, treatment 2 refers to 
radioactive implants and treatment 3 is a 
combination treatment. Few patients in the data 
source had treatments 2 or3, thus, those are the 
smallest groups. 
 
Results 
After calculating alpha and beta values for the 
NHPP for each treatment, results were compared 
and emerging patterns observed. Because the 
Caucasian race is the major population and 
ductal patients are the dominate type, this study 
focused on Caucasian ductal breast cancer 
patients. The estimation of the parameter is 
shown in Table 1. 
Figure 4 shows the pattern for the key 
parameter beta. For example, 11β  is 1.11 which 
means if a patient does not receive any 
treatment, the patient’s condition will likely 
become worse because this indicates tumor 
growth which will lead to the progression of 
cancer. It may lead the patient to move from 
stage I to stage II or higher. Examining 31β  and 
32β , it is possible to determine whether a patient 
who receives treatment 3 in stage I will have a 
better result than a patient who receives the 
same treatment as a patient in stage II. 
It was found that, for cases when beta 
are less than one, a decreased tumor size is 
indicated, meaning the treatment for breast 
cancer works. Results show that patients in early 
stages (for example, I and II) without treatment 
will experience increased tumor size and shorter 
time until death (see Table 1). Beam radiation  
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Figure 4: Evaluation Chain for NHPP 
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= 0.8635
= 1.1678
= 1.195
= 1.076
= 0.929
Stage II Patients Stage III & IV Patients
 
 
 
 
 
Table 1: Parameter Estimation for NHPP 
  Stage I Stage II 
Alpha 
Without Treatment 94.5112 113.8267 
With Treatment 1 56.17724 92.982 
With Treatment 2 76.03755 66.60 
With Treatment 3 33.8427 41.35 
Beta 
Without Treatment 1.110023 1.167756 
With Treatment 1 0.9943948 1.1195 
With Treatment 2 1.112772 1.076 
With Treatment 3 0.8635 0.929 
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(treatment 1) works for stage I but not for stage 
II. Radioactive implants (treatment 2) do not 
work well for either stage I or II. Treatment 3, a 
combination of the treatments, works well in 
stages I and II. (There is not enough data to 
conduct the NHPP for stages III and IV.) 
Intensity function plots are shown in Figures 5 - 
12. 
Figure 5 shows that, as the cumulative 
time of a patient increases, the intensity function 
also increases: this indicates, as expected, that 
tumor size is increasing and cancer is 
progressing. This result verifies the result 
obtained from parameter estimate 11β . Figure 6 
shows that, as the cumulative time of a patient 
increases, the intensity function also decreases; 
this indicates, as expected, that the cancer will 
decrease with treatment 1 for stage I ductal 
Caucasian patients. This result leads to the same 
result obtained from parameter estimate 12β . 
Figure 7 shows that, as the cumulative 
time of a patient increases, the intensity function 
also increases; this indicates, as expected, that 
the cancer progresses without treatment. This 
result verifies the result obtained from parameter 
estimate 13β . Figure 8 shows that, as the 
cumulative time of a patient increases, the 
intensity function decreases; this indicates that 
the cancer will improve with treatment 1 for 
stage 1 ductal Caucasian patients. This result 
leads to the same result obtained from the 
parameter estimate 14β . 
Following a similar method, Figures 9, 
10 and 11 show that, as the cumulative time of a 
patient increases, the intensity function also 
increases. This indicates that the cancer 
progresses without treatment or with treatment 1 
or 2 for stage II ductal Caucasian patients. This 
result leads to the same result obtained from the 
parameter estimates 21β , 22β  and 23β . 
Figure 12 shows that, as the cumulative 
time of a patient increases, the intensity function 
decreases, this indicates - as expected - that the 
cancer will improve with treatment 3 for stage II 
ductal Caucasian patients. This result attests to 
the estimation obtained from parameter estimate 
24β  (see Table 1). 
In summary, results indicate that, for 
Caucasian ductal breast cancer patients, it would 
be recommended to provide either a 
combination or a beam radiation treatment when 
they are in early stages I and II.  
 
Conclusion 
Based on breast cancer patients from the SEER 
database, adequate data exists to apply the 
NHPP analysis to Caucasian ductal cancer 
female patients in two early stages. Based on the 
results obtained from applying the proposed 
model, the following conclusions are put forth: 
 
• With no treatment, the intensity function in 
stage I and stage II increases exponentially, 
implying that the tumor size of the patients 
increases at the same rate. 
 
• With treatment 1 (beam radiation) in stage I 
the intensity function decreases, implying 
that the tumor size decreases. However, the 
same treatment in stage II shows the 
opposite result. 
 
• With treatment 2 (radioactive implants) the 
intensity function in stage I increases and 
similar behavior is observed for the same 
treatment in stage II, this implies that the 
tumor size of the patients increases at the 
same rate. 
 
• With treatment 3 (combination treatment) 
the intensity function in stages I and II 
decreases exponentially, this implies that the 
tumor size of the patients decreases at the 
same rate. 
 
The study reported here is part of a larger, 
ongoing study. We will continue to obtain data 
and, eventually to construct a NHPP for each 
stage and each tumor size available for all 
treatments and compare the results. With more 
data and a broader range of patients and cancer 
stages, it will be possible to make suggestions 
for the particular treatment that will be best for 
patients with a particular tumor size. NHPP may 
also be applied to Bayesian survival analysis to 
compare and improve results. 
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Figure 5: Stage I Breast Cancer Intensity Function 
without Treatment 
 
 
 
 
Figure 7: Stage I Breast Cancer Intensity Function 
with Treatment 2 
100 200 300 400
0.
01
4
0.
01
5
0.
01
6
0.
01
7
patients
in
te
ns
ity
 
Figure 6: Stage I Breast Cancer Intensity Function 
with Treatment 1 
 
 
 
 
Figure 8: Stage I Breast Cancer Intensity Function 
with Treatment 3 
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Figure 9: Stage II Breast Cancer Intensity Function 
without Treatment 
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Figure 11: Stage II Breast Cancer Intensity Function 
with Treatment 2 
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Figure 10: Stage II Breast Cancer Intensity Function 
with Treatment 1 
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Figure 12: Stage II Breast Cancer Intensity Function with 
Treatment 3 
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